Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
DC CAFC
First Claim
1. A method for prophylaxis or treatment of benign prostatic hyperplasia comprising administering to a person in need thereof an effective amount of an inhibitor of phosphodiesterase (PDE) V excluding a compound selected from the group consisting ofdipyridamole,2-(N-(4-carboxypiperidine)-6-chloro-4(3,4-(methylendioxy)benzyl)amino)quinazoline,2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate.4((3,4-(methylendioxy)benzyl 1)amino)-6,7,8-trimethoxy-quinazoline,1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole [4,5]pyrimidin-4(5H)one, 2-n-butyl-5-chloro-1-(2-chlorobenzyl)-4-methylacetate-imidazole,1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one,7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxy-propoxy)-2-carboxy-2,3-didehydro-chro nan-4-one,1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one,and pharmacologically compatible salts thereof.
4 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of
- a) 2-(2-propoxy-phenyl)-8-azapurin-6-one (zaprinast);
- b) dipyridamole;
- c) 1-(3-chlorophenylamino)-4-phenylphthalazine (M5445);
- d) 2-(N-(4-carboxypiperidine-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355);
- e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701);
- f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxy-quinazoline;
- g) 1-methly-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (sildenafil);
- i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one (WIN 58237);
- j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy-2,3-didehydro-chronan-4-one (PPL-557212);
- k) quinazolines and their trimethoxy derivatives;
- l) Pyrazolopyrimidones;
- as well as pharmacologically compatible salts thereof,
- quinazolines and their trimethoxy derivatives, pyrazolopyrimidones or compatible salts thereof, in local and systemic administration.
3 Citations
3 Claims
-
1. A method for prophylaxis or treatment of benign prostatic hyperplasia comprising administering to a person in need thereof an effective amount of an inhibitor of phosphodiesterase (PDE) V excluding a compound selected from the group consisting of
dipyridamole, 2-(N-(4-carboxypiperidine)-6-chloro-4(3,4-(methylendioxy)benzyl)amino)quinazoline, 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate. 4((3,4-(methylendioxy)benzyl 1)amino)-6,7,8-trimethoxy-quinazoline, 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole [4,5]pyrimidin-4(5H)one, 2-n-butyl-5-chloro-1-(2-chlorobenzyl)-4-methylacetate-imidazole, 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one, 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxy-propoxy)-2-carboxy-2,3-didehydro-chro nan-4-one, 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one, and pharmacologically compatible salts thereof.
Specification
-
- Resources
-
Current AssigneeErfindergemeinschaft Uropep Gbr, Uropep Biotech GBR
-
Original AssigneeUropep Biotech GBR
-
InventorsForssmann, Wolf-Georg, Stief, Christian Georg, Uckert, Stefan, Jonas, Udo, Tru, Michael Carsten
-
Primary Examiner(s)Anderson, James D
-
Application NumberUS13/339,561Publication NumberTime in Patent Office943 DaysField of SearchUS Class Current514/261.1CPC Class CodesA61K 31/4162 condensed with heterocyclic...A61K 31/4174 Arylalkylimidazoles, e.g. o...A61K 31/445 Non condensed piperidines, ...A61K 31/502 ortho- or peri-condensed wi...A61K 31/517 ortho- or peri-condensed wi...A61K 31/519 ortho- or peri-condensed wi...A61K 31/52 Purines, e.g. adenineA61P 13/08 of the prostateA61P 15/10 for impotence
